Skip to main content

Peer Review reports

From: Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

Original Submission
24 Nov 2023 Submitted Original manuscript
5 Dec 2023 Reviewed Reviewer Report
15 Dec 2023 Reviewed Reviewer Report
13 Feb 2024 Author responded Author comments - Patricia Pozo-Rosich
20 Feb 2024 Reviewed Reviewer Report
22 Feb 2024 Reviewed Reviewer Report
6 Mar 2024 Author responded Author comments - Patricia Pozo-Rosich
Resubmission - Version 2
13 Feb 2024 Submitted Manuscript version 2
Publishing
7 Mar 2024 Editorially accepted
15 Mar 2024 Article published 10.1186/s10194-024-01747-w

You can find further information about peer review here.

Back to article page